In September 2018, the Centers for Medicare & Medicaid Services (CMS) sent an email announcing that it would no longer cover Auryxia®. Auryxia® is an FDA approved medicine that treats iron deficiency ...

Keryx’s Auryxia has so far struggled to get off the ground. But after winning its second FDA approval, the company’s now prepping for a launch that it thinks can take the drug to the next level.

Please provide your email address to receive an email when new articles are posted on . Keryx Biopharmaceuticals Inc. said it has started shipping Auryxia (ferric citrate) tablets to wholesalers in ...

Auryxia is the only oral treatment option available today developed and approved specifically for adults living with iron deficiency anemia and chronic kidney disease, not on dialysis One in seven ...

BOSTON, MA, June 24, 2015 – Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced ...

At any point during the 16-week efficacy period, 52.1% (n=61/117) of the Auryxia treated group demonstrated hemoglobin levels of ≥1g/dL compared to 19.1% (n=22/115) of the placebo group. The Food and ...

(RTTNews) - Akebia Therapeutics, Inc. (AKBA) Thursday announced positive results from its Phase 4 collaborative study, IMPACT, which examined the effects of Auryxia or ferric citrate as the primary ...

Akebia Therapeutics, a small Cambridge, Mass.-based drugmaker, has filed a lawsuit against CMS, claiming Medicare’s denial to cover its anemia drug violates the law, according to STAT. Akebia’s only ...

DUBLIN--(BUSINESS WIRE)--The "Drug Analysis: Auryxia" drug pipelines has been added to ResearchAndMarkets.com's offering. Auryxia (ferric citrate; Keryx Biopharmaceuticals/Japan Tobacco/Torii ...

Akebia Therapeutics, Inc.'s drug Vadadustat, known as Vafseo, received FDA approval for the treatment of anemia in adults on dialysis, offering improved anemia management for a large patient ...